Brian T. Hill, MD, PhD

Articles

Considerations for Selection and Use of Frontline Therapy in Mantle Cell Lymphoma

December 23rd 2021

Shared insight on the optimal selection and use of frontline therapy for patients who present with mantle cell lymphoma.

An Overview of Mantle Cell Lymphoma and Frontline Therapy

December 23rd 2021

Expert panelists discuss a number of recent updates in B-cell lymphoma, particularly mantle cell lymphoma, follicular lymphoma and marginal zone lymphoma, that were presented at key conferences in 2021.

Dr. Hill on the Utility of BTK Inhibitors in Relapsed/Refractory MCL

December 2nd 2020

Brian T. Hill, MD, PhD, discusses the utility of BTK inhibitors in relapsed/refractory mantle cell lymphoma.

Dr. Hill on the Approval of Brexucabtagene Autoleucel in MCL

November 4th 2020

Brian T. Hill, MD, PhD, discusses the approval of brexucabtagene autoleucel in mantle cell lymphoma.

Dr. Hill on Next Steps for Research Exploring CAR T-Cell Therapy in MCL

October 26th 2020

Brian T. Hill, MD, PhD, discusses next steps for research examining CAR T-cell therapy in mantle cell lymphoma.

Dr. Hill on the Impact of the COVID-19 Pandemic in MCL

October 21st 2020

Brian T. Hill, MD, PhD, discusses the impact of the coronavirus disease 2019 pandemic on patients with mantle cell lymphoma.

Dr. Hill on the FDA Approval of Brexucabtagene Autoleucel in Relapsed/Refractory MCL

October 20th 2020

Brian T. Hill, MD, PhD, discusses the FDA approval of brexucabtagene autoleucel for patients with relapsed/refractory mantle cell lymphoma.

Dr. Hill on Future Research With CAR T-Cell Therapy in B-Cell Lymphomas

October 12th 2020

Brian T. Hill, MD, PhD, discusses future research with CAR T-cell therapy in hematologic malignancies.

Dr. Hill on Managing CRS in Patients Treated With CAR T-Cell Therapy

October 9th 2020

Brian T. Hill, MD, PhD, discusses the management of cytokine release syndrome in patients with hematologic malignancies who are treated with CAR T-cell therapy.

Dr. Hill on the Impact of Recent Approvals in Relapsed/Refractory DLBCL

September 23rd 2020

Brian T. Hill, MD, PhD, discusses the impact of recent regulatory approvals in relapsed/refractory diffuse large B-cell lymphoma.

Dr. Hill on the SADAL Trial With Selinexor in DLBCL

September 22nd 2020

Brian T. Hill, MD, PhD, discusses the data from the SADAL trial that led to the FDA approval of selinexor for use in patients with diffuse large B-cell lymphoma.

Dr. Hill on the Role of CAR T-Cell Therapy in Relapsed/Refractory DLBCL

September 11th 2020

Brian T. Hill, MD, PhD, discusses the role of CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma.

Dr. Hill on the Challenges of Managing Heavily Pretreated DLBCL

September 2nd 2020

Brian T. Hill, MD, PhD, discusses the challenges of managing heavily pretreated patients with diffuse large B-cell lymphoma.

Dr. Hill on the Safety Profile of Selinexor in Relapsed/Refractory DLBCL

June 24th 2020

Brian T. Hill, MD, PhD, discusses the safety profile of selinexor in relapsed/refractory diffuse large B-cell lymphoma.

Dr. Hill on the FDA Approval of Selinexor in DLBCL

June 22nd 2020

Brian T. Hill, MD, PhD, discusses the FDA approval of selinexor (Xpovio) in diffuse large B-cell lymphoma (DLBCL).

Dr. Hill on Resistance to BTK Inhibition in CLL

January 16th 2019

Brian T. Hill, MD, PhD, assistant professor, Hematology and Oncology, Cleveland Clinic, discusses resistance to BTK inhibition in chronic lymphocytic leukemia (CLL).

Dr. Hill Discusses the Progression of CLL Treatment

November 8th 2018

Brian T. Hill, MD, PhD, assistant professor, Hematology and Oncology, Cleveland Clinic, discusses the progression of treatment of patients with chronic lymphocytic leukemia.

Dr. Hill Discusses the Treatment Landscape of CLL

October 31st 2018

Brian T. Hill, MD, PhD, assistant professor, Hematology and Oncology, Cleveland Clinic, discusses the treatment landscape of chronic lymphocytic leukemia.

Dr. Hill on Recent Advances in Treatment of CLL

October 9th 2018

Brian T. Hill, MD, PhD, assistant professor, Hematology and Oncology, Cleveland Clinic, discusses recent advances in the treatment of patients with chronic lymphocytic leukemia.

Dr. Hill Discusses Biomarker Research in MCL

March 22nd 2018

Brian T. Hill, MD, PhD, assistant professor, Hematology and Oncology, Cleveland Clinic, discusses biomarker research in mantle cell lymphoma (MCL).